Nutriband Inc. (NASDAQ: NTRB) has announced that its Chairman and Co-Founder, Serguei Melnik, will present at NobleCon21, Noble Capital Markets' annual emerging growth equity conference. The presentation is scheduled for Dec. 3 at 9:30 a.m. Eastern at Florida Atlantic University’s Executive Education Complex in Boca Raton, Florida. This event provides Nutriband with a platform to showcase its innovative transdermal pharmaceutical products, particularly its lead product under development: an abuse-deterrent fentanyl patch incorporating the AVERSA™ abuse-deterrent technology.
The AVERSA™ technology is designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. It can be incorporated into any transdermal patch, offering a significant advancement in addressing the opioid crisis. The presentation at NobleCon21 is an opportunity for investors and industry stakeholders to gain insights into Nutriband's strategic direction and technological developments.
Investors and guests can attend the conference at a discounted rate using the code NTRBNOBLECON. A high-definition webcast of the presentation will be available the following day at nobleconference.com and Channelchek.com, where it will remain archived for 90 days. This accessibility ensures that a wider audience can benefit from the information shared during the presentation.
Nutriband's focus on transdermal drug delivery systems positions it in a specialized segment of the pharmaceutical industry. The company's commitment to developing abuse-deterrent formulations addresses a critical need in pain management, potentially reducing the risks associated with opioid medications. The presentation at NobleCon21 could attract potential partners and investors interested in supporting solutions to the opioid epidemic.
For more information about Nutriband and its technologies, visit the company's website at www.nutriband.com. The latest news and updates relating to NTRB are also available in the company’s newsroom at https://nnw.fm/NTRB.
